Adalimumab biosimilar (Weimingdamu Biotech)

阿达木单抗生物类似药（安徽未名达木生物医药）

Report date: 2022/03/14 10:22:21

Base Information

Drug NameAdalimumab biosimilar (Weimingdamu Biotech)
Drug Alias Name重组抗TNFα全人源单克隆抗体注射液（安徽未名达木生物医药）Recombinant human anti-TNFα monoclonal antibody (Weimingdamu Biotech)阿达木单抗生物仿制药（安徽未名达木生物医药）重组抗TNFα全人源单克隆抗体（安徽未名达木生物医药）
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanBiologics > Biosimilar
Mechanisms of ActionTumor necrosis factor α inhibitors
TargetsTumor necrosis factor α
Therapy Area/IndicationsArthritis, Rheumatoid
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesAnhui Weiming Damu Biomedicine Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesAnhui Weiming Damu Biomedicine Co Ltd
Inactive CompaniesN/A
Active IndicationsArthritis, Rheumatoid
Inactive IndicationsN/A

Other Information

ATC CodeL04AB04
Related LinksN/A